{"prompt": "['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 24 of 122', 'Figure 1: Study Schematic', 'Screening', 'Randomization', '2:1', 'AR101 +', 'Standard of Care', 'Initial Dose', 'Day 1: 0.5-6 mg', 'Not tolerated', 'Escalation', 'Day 2: 3 mg', 'Up-Dosing', '3-300 mg/day, 22-40 weeks', '300 mg/day for 2 weeks', 'Standard of Care', 'not tolerated', 'within 40 weeks', '300 mg/day, approximately 12 mo', 'OLFC after approximately', 'At least 300 mg', 'OLFC after', 'Maintenance', '6 mo of maintenance', 'peanut protein not', 'tolerated at OLFC', 'approximately', 'Optional RWPC if tolerated', '12 mo', '1000 mg peanut protein', 'y', 'Study Exit', 'Early', '(study completion) [1,2]', 'Discontinuation [2]', 'AR101 + standard of care: Scheduled visits are day 1, day 2, every 2 weeks during up-dosing (22-40 weeks,', 'approximately 6 months), and every 4 weeks during maintenance (52 weeks, approximately 12 months) until study exit', '(completion), with an OLFC after approximately 6 months of maintenance and RWPC (if applicable) within 4 weeks', '(preferably within 1 week) after the OLFC. Questionnaires are completed before randomization and approximately', 'every 3 months thereafter.', 'Standard of care: Scheduled visits are approximately every 3 months for approximately 18 months until study exit', '(completion), with an OLFC approximately 12 months after randomization. Questionnaires are completed before', 'randomization and approximately every 3 months thereafter.', '[1] Subjects will have the option to receive AR101 in an open-label follow-on study.', '[2]', 'Subjects with unresolved adverse events at early discontinuation or study exit or who had GI adverse events of', 'interest will have safety follow-up. Subjects who discontinue AR101 treatment early before completing 9 months', 'of maintenance and their parents/caregivers will complete relevant follow-up HRQOL questionnaires.', 'GI, gastrointestinal; HRQOL, health-related quality of life; mo, months; OLFC, open-label food challenge;', 'RWPC, real-world peanut challenge.', '3.3 Blinding', 'AR101 treatment will be open label. All subjects, study site personnel (including', 'investigators), and sponsor staff and its representatives will be unblinded to treatment', 'identity.', '3.4', 'Duration of Study', 'The total duration of treatment (AR101 treatment or standard of care alone) is approximately', '18 months for each subject.']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 25 of 122', 'The total duration of the study is approximately 30 months (subject to delays during', 'up-dosing or food challenges), assuming an approximate 6-month enrollment period and', '24 months between the first subject screened and the last assessment for the last subject.', 'The end of the study is defined as the last assessment for the last subject in the study.', '4 SELECTION OF STUDY POPULATION', 'The specific eligibility criteria for selection of subjects are provided in Section 4.1 and', 'Section 4.2. The sponsor will not grant any eligibility waivers.', '4.1', 'Inclusion Criteria', 'Each subject eligible to participate in this study must meet all the following criteria:', '1. Aged 4 to 17 years, inclusive, at screening.', '2. Written informed consent from subjects, as appropriate per local requirements, and legal', 'guardian/parent (or both parents where required by local authorities) of subjects who are', 'minors.', '3. Written assent from subjects who are minors, as appropriate per local requirements.', '4. Written informed consent from the parent/caregiver who will complete relevant', 'questionnaires during the study.', '5. History of physician-diagnosed immunoglobulin (Ig) E-mediated peanut allergy that', 'includes the onset of characteristic signs and symptoms of allergy within 2 hours of', 'known oral exposure to peanut or peanut-containing food. In general, characteristic signs', 'and symptoms of IgE-mediated allergic reactions are objective and affect the target', 'organs of skin, gastrointestinal (GI) tract, upper/lower respiratory tract, cardiovascular', 'system, or a combination of target organs as follows:', 'System', 'Examples of Symptoms (Sampson, 2014)', 'Cutaneous', 'Pruritus, erythema/flushing, urticaria, angioedema, contact urticaria', 'Ocular', 'Pruritus, tearing, conjunctival injection, periorbital edema', 'Upper respiratory tract', 'Pruritus, nasal congestion, rhinorrhea, sneezing, hoarseness, laryngeal', 'edema', 'Lower respiratory tract', 'Cough, wheezing, dyspnea, chest tightness/pain', 'Gastrointestinal', 'Oral pruritus, oral angioedema (lips, tongue, or palate), colicky', 'abdominal pain, nausea, emesis, diarrhea', 'Cardiovascular', 'Tachycardia, dizziness, hypotension, loss of consciousness/fainting', 'Other', 'Sense of impending doom, uterine cramping/contractions', '6. Mean wheal diameter on SPT to peanut > 8 mm greater than the negative saline control at', 'screening.', '7. Serum IgE to peanut of > 14 kUA/L at screening.']\n\n###\n\n", "completion": "END"}